DUBLIN–(BUSINESS WIRE)–The “Cephalosporin
Drugs: Global Market Analysis & Outlook 2019-2024” report
has been added to ResearchAndMarkets.com’s offering.
Market Overview
-
The major factors for the growth of the cephalosporin drugs market
include the rising demand for anti-microbial in various indications,
rising prevalence of infectious diseases, and increasing use of
combination therapies. -
Most of the small companies out-license the products after taking them
through the early clinical development phase. These agreements usually
include one-time payment for obtaining the rights, in addition to the
milestone payments on completing designated developmental phase and
royalties on sales. There are over 50 cephalosporin drugs that have
been approved in the past five decades, and almost half of them are
for the antibacterial activity. However, new cephalosporins
(classified as the fifth-generation), which are used for the treatment
of serious gram-negative bacterial infections, including
methicillin-resistant Staphylococcus aureus (MRSA), were recently
approved. -
Manufacturers are involved in the development of new drugs to fight
against anti-microbial resistance. The complexity and diversity of
resistance mechanisms have defined the need for new and improved
-lactam antibiotics. Additionally, the companies are involved in the
strategic development of new products, for example, in 2017, Shionogi
& Co. Ltd collaborated with the F. Hoffmann-La Roche Ltd for the
development and commercialization of baloxavir marboxi. -
Thus, owing to the all above-mentioned factors the cephalosporin drugs
market is expected to witness high growth over the forecast period.
Key Market Trends
The Fifth-generation Segment is Expected to Account for the Largest
Market Share During the Forecast Period
The fifth-generation cephalosporins were developed in the lab to
specifically target resistant strains of bacteria. In particular,
ceftobiprole is effective against methicillin-resistant staphylococcus
aureus (MRSA). These agents are sometimes referred to as the advanced
generation, rather than fifth-generation cephalosporins. Cephalosporins
exhibit side effects similar to penicillin, and drug-allergy and
hypersensitivity.
Cephalosporins, in general, have been associated with little
hepatotoxicity and rare instances of drug-induced liver injury. The
fifth-generation cephalosporins include Ceftobiprole, Ceftaroline, and
Ceftolozane. Ceftobiprole has powerful antipseudomonal characteristics
and appears to be less susceptible to the development of resistance.
Ceftaroline has also been described as the “fifth-generation”
cephalosporin, but does not have the antipseudomonal or VRE coverage of
ceftobiprole. The market for Ceftolozane is growing at a good pace, as
it has opened gates for an alternative for the treatment of complicated
intra-abdominal infections (CIAI) and complicated urinary tract
infections (CUTI).
Furthermore, Ceftolozane is combined with the -lactamase inhibitor
tazobactam, as multi-drug resistant bacterial infections generally
exhibit resistance to all -lactam antibiotics, unless this enzyme is
inhibited. Hence, the increase in the use of combination therapies is
expected to drive the market during the forecast period.
Asia-Pacific is Expected to be the Fastest Growing Region
Asia-Pacific is expected to dominate this market, due to the high
prevalence of infectious diseases, increasing healthcare expenditure,
and a large population base. Furthermore, the demand for better
healthcare infrastructure and government initiatives is expected to help
the growth of the market in this region.
As per the statistics published by the World Health Organization (WHO)
TB statistics for India for 2016, an estimated incidence of tuberculosis
(TB) is 2.79 million cases in India. Thus, rising cases of various
infections are expected to boost the overall growth of the market.
Asia-Pacific is followed by Europe, due to its large base of geriatric
population and rising prevalence of infectious diseases in several
countries of the region.
Competitive Landscape
The market studied is fragmented, owing to the presence of many small
and large market players. Some of the market players are Astellas Pharma
Inc., Baxter International, F. Hoffmann-La Roche AG, GlaxoSmithKline
PLC, Lupin Pharmaceuticals, Macleods Pharmaceuticals Ltd., Mankind
Pharma, Merck & Co. Inc., Pfizer Inc., and Teva Pharmaceuticals.
Key Topics Covered
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Anti-microbials in Various Indications
4.2.2 Rising Prevalence of Infectious Diseases
4.2.3 Increasing Use of Combination Therapies
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines
4.3.2 Weak Pipeline Molecules
4.4 Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Generation
5.1.1 First-generation
5.1.2 Second-generation
5.1.3 Third-generation
5.1.4 Fourth-generation
5.1.5 Fifth-generation
5.2 By Prescription Type
5.2.1 Prescription Drugs
5.2.2 OTC Drugs
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aristo Pharmaceuticals Ltd.
6.1.2 Baxter International
6.1.3 F. Hoffmann-La Roche AG
6.1.4 GlaxoSmithKline PLC
6.1.5 Lupin Pharmaceuticals Inc.
6.1.6 Macleods Pharmaceuticals Ltd.
6.1.7 Mankind Pharma
6.1.8 Merck & Co. Inc.
6.1.9 Pfizer Inc.
6.1.10 Teva Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/qhewna
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Antibiotics